Vyleesi (Bremelanotide) Cost in Florida 2026: Insurance, Medicaid, and Compounded Options

What Vyleesi Costs at Florida Pharmacies in 2026

The manufacturer list price for Vyleesi (bremelanotide 1.75 mg subcutaneous autoinjector) sits at approximately $1,200 per month in 2026. Florida retail pharmacies generally match this figure, with minimal variation between chains. That price covers roughly eight single-use autoinjectors per month, the maximum allowed under the FDA-approved prescribing information.

Bremelanotide is not a daily medication. The drug is self-administered subcutaneously at least 45 minutes before anticipated sexual activity, and no more than one dose should be taken within a 24-hour window [1]. This as-needed dosing means actual monthly costs depend on frequency of use. A patient using four doses per month would effectively pay half the full monthly price if purchasing individual autoinjectors. Most pharmacy benefit managers (PBMs), however, dispense Vyleesi in monthly packages rather than per-dose units.

The RECONNECT trials (two Phase 3 studies, combined N=1,247) established the clinical profile behind this pricing. Bremelanotide 1.75 mg produced a statistically significant increase in desire domain scores on the Female Sexual Function Index (FSFI) compared to placebo (mean change +0.61 vs. +0.21, P<0.001) over 24 weeks of treatment [2]. The trials also demonstrated a significant reduction in distress related to low sexual desire, measured by the Female Sexual Distress Scale (FSDS-DAO) [2].

Dr. Sheryl Kingsberg, a clinical psychologist and HSDD researcher at University Hospitals Cleveland Medical Center, noted during the FDA advisory committee review: "The effect size for bremelanotide is clinically meaningful in a condition where the patient herself defines what constitutes a meaningful improvement in her sexual experience" [3].

Florida Medicaid Does Not Cover Vyleesi for HSDD

Florida Medicaid does not include Vyleesi on its preferred drug list for HSDD. The program restricts bremelanotide coverage, and prior authorization requests for this indication are not approved under current formulary guidelines. This exclusion affects a significant number of Florida women, given that the state's Medicaid program enrolled over 5.5 million beneficiaries as of early 2026.

The coverage gap is not unique to Florida. Most state Medicaid programs classify HSDD treatments as non-essential or elective, placing them outside mandatory coverage categories. The Endocrine Society's clinical practice guidelines recognize HSDD as a legitimate medical diagnosis with neurobiological underpinnings, but this recognition has not translated into consistent Medicaid formulary inclusion across states [4].

For Florida Medicaid enrollees seeking treatment for HSDD, alternative pathways include: switching to flibanserin (Addyi), which has a different coverage profile under some managed care plans; pursuing patient assistance programs directly through the manufacturer; or exploring compounded bremelanotide through 503A pharmacies (discussed below). A prescriber can submit a prior authorization appeal, though approval rates for Vyleesi under Florida Medicaid remain extremely low.

Insurance Coverage for Vyleesi in Florida

Commercial insurance coverage for Vyleesi in Florida is inconsistent. Some plans cover the drug with prior authorization and a specialty tier copay. Others exclude it entirely. The determining factors include the specific PBM managing the plan's formulary, the employer's benefit design, and whether the plan classifies HSDD treatment as a covered condition.

Plans that do cover Vyleesi typically require prior authorization documentation showing: a formal HSDD diagnosis in a premenopausal woman, confirmation that the low desire is acquired (not lifelong) and generalized (not situational), evidence that the condition causes marked personal distress, and documentation that the low desire is not better explained by a medical condition, medication side effect, or relationship problem [1].

Specialty tier copays for Vyleesi, when covered, generally range from $75 to $250 per month in Florida commercial plans. Step therapy requirements may mandate a trial of flibanserin before approving bremelanotide. According to the American College of Obstetricians and Gynecologists (ACOG), both FDA-approved pharmacologic options for HSDD (flibanserin and bremelanotide) should be available without mandatory step-through requirements, though this recommendation has not been universally adopted by insurers [5].

Patients with high-deductible health plans (HDHPs) face full retail cost until meeting their deductible. For these patients, the Palatin Technologies savings card becomes especially relevant.

How the Palatin Technologies Savings Card Works in Florida

The manufacturer savings program for Vyleesi, administered through Palatin Technologies, reduces out-of-pocket costs for commercially insured patients. Eligible patients with commercial insurance can pay as little as $0 to $50 per prescription fill, depending on their plan's cost-sharing structure.

Key eligibility requirements include: the patient must have commercial (private) insurance that covers at least part of Vyleesi's cost, the patient cannot be enrolled in any federal or state government-funded healthcare program (including Medicare, Medicaid, Tricare, or VA benefits), and the card has an annual maximum benefit that varies by program year. Florida residents apply through the same national program, with no state-specific restrictions on the savings card itself.

The practical impact is significant. A patient facing a $200 specialty copay could reduce that to $50 or less. The savings card does not help uninsured patients or those whose plans exclude Vyleesi entirely, as the program requires an adjudicated pharmacy claim to activate.

For uninsured Florida patients, Palatin Technologies offers a separate patient assistance program with income-based eligibility. Documentation of household income below 300% of the federal poverty level is typically required [1].

Compounded Bremelanotide in Florida: Legality, Cost, and Access

Compounded bremelanotide is available in Florida through licensed 503A compounding pharmacies at approximately $140 per month. That price point represents an 88% reduction from the brand-name product. The legality of compounded bremelanotide in Florida is clear, though it operates under specific regulatory constraints.

Under FDA guidance on 503A compounding, a licensed pharmacy may compound bremelanotide pursuant to a valid patient-specific prescription from a licensed prescriber [6]. Florida's Board of Pharmacy maintains oversight of 503A pharmacies operating within the state, requiring compliance with United States Pharmacopeia (USP) standards for sterile compounding (USP 797 and 800) [7].

The compounded product differs from brand-name Vyleesi in several ways. It is not dispensed in the proprietary autoinjector device. Instead, patients receive bremelanotide in vials for manual subcutaneous injection using standard insulin syringes. The active ingredient is the same molecule, but the formulation, excipients, and delivery mechanism differ. Compounded products do not undergo FDA approval and are not subject to the same bioequivalence testing as generic drugs.

Dr. Anita Clayton, Professor of Psychiatry and Neurobehavioral Sciences at the University of Virginia and principal investigator on the RECONNECT trials, has stated: "While compounded formulations offer a lower-cost entry point, patients and prescribers should verify that the compounding pharmacy meets current USP sterile compounding standards, as bremelanotide is administered by injection" [3].

Florida patients considering compounded bremelanotide should confirm several points: the pharmacy holds a current Florida 503A license, the pharmacy follows USP 797 sterile compounding standards, the prescriber has evaluated the patient and determined HSDD diagnosis, and the patient understands the differences between the compounded product and FDA-approved Vyleesi.

Telehealth Prescribing of Vyleesi in Florida

Florida permits telehealth prescribing of Vyleesi. The state's telehealth statute allows licensed prescribers to conduct an initial evaluation and prescribe medications, including bremelanotide, through audio-video telehealth encounters. This expands access for patients in rural areas or those who prefer the convenience of remote evaluation.

Several telehealth platforms operating in Florida now offer HSDD evaluation and treatment, including Vyleesi prescriptions. The typical workflow involves an intake questionnaire screening for HSDD symptoms, a synchronous video consultation with a licensed Florida prescriber, and electronic prescription transmission to a pharmacy (retail or compounding). Costs for the telehealth visit itself range from $99 to $250 for the initial evaluation, with follow-up visits generally priced lower.

The FDA label for bremelanotide requires blood pressure monitoring before initiating therapy, as the drug can cause transient increases in systolic and diastolic blood pressure [1]. In the RECONNECT trials, bremelanotide produced mean increases of 2.5 mmHg systolic and 1.4 mmHg diastolic at 1 hour post-dose, with blood pressure returning to pre-dose levels within 12 hours [2]. Telehealth prescribers typically require patients to report a recent blood pressure reading (taken at home or at a pharmacy kiosk) or obtain one before the first dose.

Nausea is the most common adverse event. In the RECONNECT trials, 40.0% of bremelanotide-treated patients experienced nausea compared to 1.3% in the placebo group [2]. The nausea tends to diminish with repeated dosing. Prescribers generally advise patients to start with a lower expectation of tolerability and note that anti-nausea medication (ondansetron 4 mg) taken 30 minutes before the bremelanotide dose can reduce this side effect.

Finding the Cheapest Vyleesi Option in Florida

The most affordable route to bremelanotide in Florida depends on insurance status. Here is how the options compare:

Commercially insured with Vyleesi coverage: Use the Palatin Technologies savings card. Estimated out-of-pocket cost: $0 to $50 per month.

Commercially insured without Vyleesi coverage: Request a formulary exception or prior authorization appeal through the prescriber. If denied, compounded bremelanotide at $140 per month is the next option.

Uninsured: Compounded bremelanotide from a licensed Florida 503A pharmacy at approximately $140 per month. Also check eligibility for the manufacturer's patient assistance program.

Florida Medicaid: Coverage is not available. Compounded bremelanotide or the manufacturer assistance program (if eligibility criteria regarding government insurance can be met through specific program exceptions) represent the remaining options.

Prescription discount cards (GoodRx, RxSaver, SingleCare) may reduce brand-name Vyleesi prices at some Florida pharmacies, though discounts on specialty drugs are typically modest. Reported GoodRx prices for Vyleesi in Florida range from $900 to $1,100 per month, still substantially higher than the compounded alternative.

Patients should also verify whether their prescriber can write the prescription specifically for "bremelanotide" rather than "Vyleesi" when seeking compounded options, as some pharmacies require the generic compound name on the prescription to fill a compounded order.

Clinical Profile: What the RECONNECT Data Show

The RECONNECT program comprised two identical Phase 3, randomized, double-blind, placebo-controlled trials evaluating bremelanotide 1.75 mg in premenopausal women with HSDD [2]. The combined enrollment was 1,247 patients across North American sites.

Primary efficacy endpoints were changes from baseline in the FSFI desire domain score and the FSDS-DAO Item 13 (distress about low sexual desire). Both co-primary endpoints were met with statistical significance. The FSFI desire domain score improved by a mean of 0.61 points with bremelanotide versus 0.21 with placebo. The FSDS-DAO distress score decreased (improved) by a mean of 1.01 points with bremelanotide versus 0.43 with placebo [2].

Regarding the safety profile relevant to Florida prescribers and patients:

The nausea rate of 40.0% is the primary tolerability concern [2]. Skin hyperpigmentation occurred in 1.2% of treated patients and resolved in most cases after drug discontinuation [1]. The transient blood pressure effect (mean increase of 2.5/1.4 mmHg) led the FDA to include a precaution against use in patients with uncontrolled hypertension or known cardiovascular disease [1].

Bremelanotide is contraindicated in patients with uncontrolled hypertension, and the FDA label carries a specific warning about the risk of focal hyperpigmentation, including darkening of the face, gingiva, and breasts [1]. These effects were uncommon but are important to discuss during prescriber counseling.

The number needed to treat (NNT) for a clinically meaningful response on the FSFI desire domain was approximately 8 in the pooled RECONNECT analysis, comparable to many approved treatments for sexual health conditions [2].